Evofem Biosciences, Inc. (EVFM) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US30048L3024

Price
0.01 USD
Market cap
795,180.49 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Evofem Biosciences, Inc. financials

Fiscal year2025
Revenue20.18 m USD
Gross profit15.57 m USD
Operating income3.37 m USD
EBIT2.74 m USD
Net income391,000.00 USD
Diluted EPS – continuing operations0.00 USD

Full history since 2012, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Evofem Biosciences, Inc.

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.